keyword
MENU ▼
Read by QxMD icon Read
search

comparative efficacy of ppis

keyword
https://www.readbyqxmd.com/read/29305934/efficacy-of-laparoscopic-nissen-fundoplication-vs-transoral-incisionless-fundoplication-or-proton-pump-inhibitors-in-patients-with-gastroesophageal-reflux-disease-a-systematic-review-and-network-meta-analysis
#1
Joel Richter, Ambuj Kumar, Seth Lipka, Branko Miladinovic, Vic Velanovich
BACKGROUND & AIMS: The effects of transoral incisionless fundoplication (TIF) and laparoscopic Nissen fundoplication (LNF) have been compared with those of proton pump inhibitors (PPIs) or a sham procedure in patients with gastroesophageal reflux disease (GERD), but there has been no direct comparison of TIF vs LNF. We performed a systematic review and network meta-analysis of randomized controlled trials to compare the relative efficacies of TIF vs LNF in patients with GERD. METHODS: We searched publication databases and conference abstracts through May 10, 2017 for randomized controlled trials that compared the efficacy of TIF or LNF with that of a sham procedure or PPIs in patients with GERD...
January 3, 2018: Gastroenterology
https://www.readbyqxmd.com/read/29274884/multifaceted-intervention-to-curb-in-hospital-over-prescription-of-proton-pump-inhibitors-a-longitudinal-multicenter-quasi-experimental-before-and-after-study
#2
Rosaria Del Giorno, Alessandro Ceschi, Michela Pironi, Anna Zasa, Angela Greco, Luca Gabutti
BACKGROUND: Proton pump inhibitors (PPIs) are indicated for a restricted number of clinical conditions, and their misuse can lead to several adverse effects. Despite that, the proportion of overuse is alarmingly high. OBJECTIVE: To test the efficacy of a multifaceted strategy in order to achieve a significant reduction of new PPI prescriptions at discharge in hospitalized patients. DESIGN: Multicenter longitudinal quasi-experimental before-and-after study conducted from July 1st, 2014 to June 30th, 2017...
December 20, 2017: European Journal of Internal Medicine
https://www.readbyqxmd.com/read/29226099/efficacy-and-safety-of-direct-acting-antivirals-in-hepatitis-c-virus-infected-patients-taking-proton-pump-inhibitors
#3
Karn Wijarnpreecha, Supavit Chesdachai, Charat Thongprayoon, Veeravich Jaruvongvanich, Patompong Ungprasert, Wisit Cheungpasitporn
Background and Aims: Direct-acting antiviral (DAA) therapy is the cornerstone of the treatment of chronic hepatitis C virus (HCV) infection. Eradication of HCV, predicted by the attainment of a sustained virologic response (SVR) 12 weeks following DAA therapy, is the goal of this treatment. Interestingly, recent studies have reported the possible association between HCV-infected patients with DAA therapy concomitant use of proton pump inhibitors (PPIs) and lower odds of achieving SVR. This meta-analysis was conducted to summarize all available data and to estimate this potential association...
December 28, 2017: Journal of Clinical and Translational Hepatology
https://www.readbyqxmd.com/read/29214885/short-term-efficacy-of-potassium-competitive-acid-blocker-following-gastric-endoscopic-submucosal-dissection-a-propensity-score-analysis
#4
Yohei Horikawa, Hiroya Mizutamari, Nobuya Mimori, Yuhei Kato, Saki Fushimi, Sayaka Sato, Syunji Okubo
BACKGROUND: Endoscopic submucosal dissection (ESD) is a promising method for the resection of superficial gastric neoplasms. Vonoprazan is a novel potassium-competitive acid blocker (P-CAB) that is currently considered as a potential alternative to proton pump inhibitors (PPIs) for the treatment of acid-related diseases. However, the utility of vonoprazan in ESD-related ulcers is unclear. Therefore, we compared the short-term efficacies of vonoprazan and the PPI lansoprazole in ESD-related ulcer healing during the first two weeks following intervention...
December 7, 2017: Scandinavian Journal of Gastroenterology
https://www.readbyqxmd.com/read/29199388/efficacy-and-safety-of-stress-ulcer-prophylaxis-in-critically-ill-patients-a-network-meta-analysis-of-randomized-trials
#5
REVIEW
Waleed Alhazzani, Fayez Alshamsi, Emilie Belley-Cote, Diane Heels-Ansdell, Romina Brignardello-Petersen, Mustafa Alquraini, Anders Perner, Morten Hylander Møller, Mette Krag, Saleh Almenawer, Bram Rochwerg, Joanna Dionne, Roman Jaeschke, Mohammed Alshahrani, Adam Deane, Dan Perri, Lehana Thebane, Awad Al-Omari, Simon Finfer, Deborah Cook, Gordon Guyatt
PURPOSE: Stress ulcer prophylaxis (SUP) is commonly prescribed in the intensive care unit. However, data from systematic reviews and conventional meta-analyses are limited by imprecision and restricted to direct comparisons. We conducted a network meta-analysis of randomized clinical trials (RCTs) to examine the safety and efficacy of drugs available for SUP in critically ill patients. METHODS: We searched MEDLINE, EMBASE, and the Cochrane Library Central Register of Controlled Trials through April 2017 for randomized controlled trials that examined the efficacy and safety of proton pump inhibitors (PPIs), histamine-2 receptor antagonists (H2RAs), and sucralfate for SUP in critically ill patients...
December 4, 2017: Intensive Care Medicine
https://www.readbyqxmd.com/read/29162657/implementation-of-a-guideline-to-decrease-use-of-acid-suppressing-medications-in-the-nicu
#6
Asimenia Angelidou, Katherine Bell, Munish Gupta, Kristen Tropea Leeman, Anne Hansen
BACKGROUND AND OBJECTIVES: Acid-suppressing medications are used extensively in term and preterm newborns despite limited efficacy data and increasing evidence for potential harm. We sought to reduce nonindicated use of proton pump inhibitors (PPIs) and histamine-2 receptor antagonists (H2RAs) in our level III/IV NICU by developing and implementing a guideline for their use. Our specific aim was to reduce prescriptions among infants <1 month corrected age from a baseline of 7.5 to 4 per month by December 2016...
December 2017: Pediatrics
https://www.readbyqxmd.com/read/29161458/proton-pump-inhibitors-for-functional-dyspepsia
#7
REVIEW
Maria Ines Pinto-Sanchez, Yuhong Yuan, Ahmed Hassan, Premysl Bercik, Paul Moayyedi
BACKGROUND: Functional dyspepsia (FD or non-ulcer dyspepsia) is defined as continuous or frequently recurring epigastric pain or discomfort for which no organic cause can be found. Acid suppressive therapy, including proton pump inhibitors (PPIs), has been proposed as a therapeutic option in FD, but its efficacy remains controversial. While PPIs are generally considered safe and well tolerated, they have been associated with adverse events, especially in the long term. For this reason, decisions on whether to initiate or continue PPI therapy should be made based on an appropriate clinical indication...
November 21, 2017: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/28953640/comparative-effectiveness-and-acceptability-of-the-fda-licensed-proton-pump-inhibitors-for-erosive-esophagitis-a-prisma-compliant-network-meta-analysis
#8
Mei-Juan Li, Qing Li, Min Sun, Li-Qin Liu
BACKGROUND: This study compared the effectiveness and acceptability of all Food and Drug Administration (FDA)-recommended dose proton pump inhibitors (PPIs) in erosive esophagitis (EE): Dexlansoprazole 60 mg, Esomeprazole 40 mg, Esomeprazole 20 mg, Pantoprazole 40 mg, Lansoprazole 30 mg, Rabeprazole 20 mg, Omeprazole 20 mg. METHODS: A systematic literature search was performed using PubMed, Embase, and Cochrane Library. Totally, 25 randomized controlled trials (RCTs) met study selection criteria and were incorporated in this network meta-analysis (NMA) study...
September 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28912807/a-meta-analysis-and-systematic-review-of-the-efficacy-of-twice-daily-ppis-versus-once-daily-for-treatment-of-gastroesophageal-reflux-disease
#9
REVIEW
Hongying Zhang, Zhiping Yang, Zhen Ni, Yongquan Shi
BACKGROUND: To investigate whether PPIs BID is superior to QD for treatment of GERD in a short time. METHODS: We searched PubMed, Cochrane Library, Scopus, EMBASE, Ovid, EBSCO, and Web of Science databases (from 1998 to May 2016) to select RCTs, which compared the efficacy of PPIs BID versus QD for GERD. The primary outcomes were symptom relief or esophageal mucosal healing at weeks 4 and 8. The M-H method with fixed-effect or random-effect model was used to calculate RR and 95% CIs...
2017: Gastroenterology Research and Practice
https://www.readbyqxmd.com/read/28886027/evolutionary-analysis-and-interaction-prediction-for-protein-protein-interaction-network-in-geometric-space
#10
Lei Huang, Li Liao, Cathy H Wu
Prediction of protein-protein interaction (PPI) remains a central task in systems biology. With more PPIs identified, forming PPI networks, it has become feasible and also imperative to study PPIs at the network level, such as evolutionary analysis of the networks, for better understanding of PPI networks and for more accurate prediction of pairwise PPIs by leveraging the information gained at the network level. In this work we developed a novel method that enables us to incorporate evolutionary information into geometric space to improve PPI prediction, which in turn can be used to select and evaluate various evolutionary models...
2017: PloS One
https://www.readbyqxmd.com/read/28859382/evaluation-of-treatment-pattern-and-symptom-control-in-patients-with-gastroesophageal-reflux-disease-multihospital-questionnaire-survey-on-the-current-situation-in-korea
#11
S I Seo, C S Bang, H S Kang, M H Choi, W G Shin, H J Jang, J B Kim, K H Baik, S H Kae, H Y Kim
Proton pump inhibitors (PPIs) are the most effective treatment for gastroesophageal reflux disease (GERD); however, a considerable number of patients fail to respond to PPI therapy and complain of nocturnal heartburn and sleep disturbance. The aims of this study are to evaluate the treatment pattern of GERD-related medications and their efficacy in relieving nocturnal heartburn. A total of 334 patients with GERD receiving PPI therapy within 6 months were enrolled in a multihospital questionnaire survey from January, 2014 to March, 2015...
October 1, 2017: Diseases of the Esophagus: Official Journal of the International Society for Diseases of the Esophagus
https://www.readbyqxmd.com/read/28674348/randomized-trial-comparing-esomeprazole-and-rabeprazole-in-first-line-eradication-therapy-for-helicobacter-pylori-infection-based-on-the-serum-levels-of-pepsinogens
#12
Tadashi Shimoyama, Daisuke Chinda, Yoshihiko Sawada, Kazuo Komai, Hironobu Chiba, Yoshiharu Saito, Yoshio Sasaki, Masashi Matsuzaka, Shinsaku Fukuda
Objective CYP2C19 metabolic activity influences the efficacy of Helicobacter pylori eradication therapies comprising PPIs. Rabeprazole (RPZ) and esomeprazole (EPZ) are PPIs not extensively metabolized by CYP2C19. The aim of this study was to elucidate whether or not first-line triple therapies using RPZ or EPZ are equally effective in Japanese patients with different CYP2C19 genotypes. Methods Two-hundred patients infected with H. pylori were randomized to receive one of the following regimens: amoxicillin (750 mg), clarithromycin (200 mg), and either esomeprazole (20 mg) (EAC group) or rabeprazole (10 mg) (RAC group), twice a day for one week...
2017: Internal Medicine
https://www.readbyqxmd.com/read/28645482/proton-pump-inhibitors-and-survival-outcomes-in-patients-with-metastatic-renal-cell-carcinoma
#13
Aly-Khan A Lalani, Rana R McKay, Xun Lin, Ronit Simantov, Marina D Kaymakcalan, Toni K Choueiri
INTRODUCTION: Proton pump inhibitors (PPIs) are potent inhibitors of gastric acid secretion and can affect the optimal absorption of concomitant oral medications, such as vascular endothelial growth factor (VEGF) tyrosine kinase inhibitors (TKIs). The purpose of this study was to investigate the effect of PPI use on survival in metastatic renal cell carcinoma (mRCC) patients treated in the targeted therapy era. MATERIALS AND METHODS: We conducted a pooled analysis of mRCC patients treated in phase II and III clinical trials...
May 31, 2017: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/28584402/effects-of-patient-age-and-choice-of-antisecretory-agent-on-success-of-eradication-therapy-for-helicobacter-pylori-infection
#14
Toshihiro Nishizawa, Hidekazu Suzuki, Ai Fujimoto, Hiroto Kinoshita, Shuntaro Yoshida, Yoshihiro Isomura, Akira Toyoshima, Takanori Kanai, Naohisa Yahagi, Osamu Toyoshima
The effects of patient age on the efficacy of eradication treatment for Helicobacter pylori (H. pylori) remain unclear. The present study aimed to determine whether age affects eradication therapy involving vonoprazan, a novel potassium-competitive acid blocker (PCAB). We reviewed the cases of 3,261 patients who were administered first-line and second-line H. pylori eradication therapy at Toyoshima Endoscopy Clinic. The first-line treatment was clarithromycin and amoxicillin combined with a proton pump inhibitor (PPI) or a PCAB...
May 2017: Journal of Clinical Biochemistry and Nutrition
https://www.readbyqxmd.com/read/28567114/a-randomized-double-blind-study-to-evaluate-the-acid-inhibitory-effect-of-vonoprazan-20-mg-and-40-mg-in-patients-with-proton-pump-inhibitor-resistant-erosive-esophagitis
#15
Katsuhiko Iwakiri, Yuuichi Sakurai, Madoka Shiino, Hiroyuki Okamoto, Kentaro Kudou, Akira Nishimura, Naoki Hiramatsu, Eiji Umegaki, Kiyoshi Ashida
BACKGROUND: Standard treatment for patients with erosive esophagitis (EE) is proton-pump inhibitors (PPIs), but some patients are resistant to PPIs. We aimed to evaluate the acid-inhibitory effects and efficacy of a novel potassium-competitive acid blocker (vonoprazan) in patients with PPI-resistant EE. METHODS: This randomized, double-blind, multicenter study of vonoprazan evaluated gastric and esophageal pH over a 24-hour period as the primary endpoint and EE healing rate as the secondary endpoint...
June 2017: Therapeutic Advances in Gastroenterology
https://www.readbyqxmd.com/read/28501868/factors-associated-with-potassium-competitive-acid-blocker-non-response-in-patients-with-proton-pump-inhibitor-refractory-gastroesophageal-reflux-disease
#16
Masatsugu Okuyama, Kenichi Nakahara, Narika Iwakura, Tomoki Hasegawa, Maizumi Oyama, Ayumi Inoue, Hirotaka Ishizu, Hiroshi Satoh, Yasuhiro Fujiwara
BACKGROUND/AIMS: Approximately 20-40% of patients with gastroesophageal reflux disease (GERD) are refractory to proton pump inhibitor (PPI) treatment. The acid-inhibitory effect of vonoprazan, a novel potassium-competitive acid blocker (P-CAB), is significantly greater when compared to the effect of PPIs. We investigated the efficacy of vonoprazan treatment for PPI-refractory GERD and factors associated with P-CAB non-response. METHODS: We enrolled 277 GERD patients receiving continuous PPI therapy...
2017: Digestion
https://www.readbyqxmd.com/read/28444399/development-of-a-multipurpose-scaffold-for-the-display-of-peptide-loops
#17
Maxim Rossmann, Sandra J Greive, Tommaso Moschetti, Michael Dinan, Marko Hyvönen
Protein-protein interactions (PPIs) determine a wide range of biological processes and analysis of these dynamic networks is increasingly becoming a mandatory tool for studying protein function. Using the globular ATPase domain of recombinase RadA as a scaffold, we have developed a peptide display system (RAD display), which allows for the presentation of target peptides, protein domains or full-length proteins and their rapid recombinant production in bacteria. The design of the RAD display system includes differently tagged versions of the scaffold, which allows for flexibility in the protein purification method, and chemical coupling for small molecule labeling or surface immobilization...
June 1, 2017: Protein Engineering, Design & Selection: PEDS
https://www.readbyqxmd.com/read/28435366/comparative-evaluation-of-antimicrobial-efficacy-of-triple-antibiotic-paste-calcium-hydroxide-and-a-proton-pump-inhibitor-against-resistant-root-canal-pathogens
#18
Shibha Mehta, Promila Verma, Aseem Prakash Tikku, Anil Chandra, Rhythm Bains, Gopa Banerjee
OBJECTIVE: The objective of this study is to compare the antimicrobial efficacy of triple antibiotic paste (TAP) and a proton pump inhibitor (PPI) (omeprazole) in combination with calcium hydroxide (CH) against Enterococcus faecalis and Candida albicans. MATERIALS AND METHODS: E. faecalis and C. albicans were subcultured and inoculated at 37° overnight and were treated with different dilutions of TAP, 25 μg/ml (Group 1), CH (Group 2, control), CH 16 mg/ml + omeprazole 2 mg/ml (Group 3a) (CH 16 mg/ml + omeprazole 4 mg)/ml (Group 3b) for 24, 48, and 72 h in sterile uncoated 96-well microtiter plates...
January 2017: European Journal of Dentistry
https://www.readbyqxmd.com/read/28395507/pantoprazole-does-not-reduce-the-antiplatelet-effect-of-clopidogrel-a-randomized-controlled-trial-in-korea
#19
Yoon Jin Choi, Nayoung Kim, In-Jin Jang, Joo-Youn Cho, Ryoung Hee Nam, Ji Hyun Park, Hyun Jin Jo, Hyuk Yoon, Cheol Min Shin, Young Soo Park, Dong Ho Lee, Hyun Chae Jung
Background/Aims: Concerns that proton pump inhibitors (PPIs) diminish the efficacy of clopidogrel could hamper the appropriate prescription of PPIs. We evaluated the influence of pantoprazole on the antiplatelet effect of clopidogrel compared with ranitidine, which is regarded as safe, after stratification of the population according to the presence of a cytochrome (CYP) 2C19 polymorphism in Korea. Methods: Forty patients who underwent dual antiplatelet therapy were randomized to receive pantoprazole (n=20) or ranitidine (n=20)...
July 15, 2017: Gut and Liver
https://www.readbyqxmd.com/read/28385467/gastroesophageal-reflux-disease-related-symptom-recurrence-in-patients-discontinuing-proton-pump-inhibitors-for-bravo-wireless-esophageal-ph-monitoring-study
#20
R Schey, S P Alla, D Midani, H P Parkman
BACKGROUND: Patients with gastroesophageal reflux disease (GERD) are treated with proton pump inhibitors (PPIs). Those that do not achieve symptom relief, or non-responders, usually undergo esophageal pH monitoring off PPIs in order to confirm the presence of GERD. AIMS: To assess the efficacy of the reverse-PPI trial in evaluating the presence of GERD or its recurrence rates, as well as to identify a correlation between the symptom recurrence rates and GERD severity determined by 48-hour Bravo esophageal pH-monitor testing...
April 3, 2017: Revista de Gastroenterología de México
keyword
keyword
45167
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"